Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells

Katagiri Seiichiro, MD PhD, Kenko Azuma, PhD, Yuu Saitoh, MD, Seiichiro Yoshizawa, MD PhD, Daigo Akahane, MD PhD, Hiroaki Fujimoto, MD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko.H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 5525.

https://doi.org/10.1182/blood-2018-99-113317

Published: 2018

Journal Articles

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

Sho Kubota, PhD, Kenji Tokunaga, MD, Tomohiro Umezu, PhD, Takako Yokomizo, PhD, Motohiko Oshima, PhD, Eisaku Iwanaga, MD PhD, Norio Asou, MDPhD, Atsushi Iwama, MD PhD, Kazuma Ohyashiki, MD PhD, Motomi Osato, MD, PhD, Goro Sashida, MD PhD

Blood (2018) 132 (Supplement 1): 761.

https://doi.org/10.1182/blood-2018-99-110333

Published: 2018

Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2014) 124 (21): 1797.

https://doi.org/10.1182/blood.V124.21.1797.1797

Published: 2014

Journal Articles

Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients

Seiichiro Yoshizawa, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Shinsuke Iida, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1879.

https://doi.org/10.1182/blood.V122.21.1879.1879

Published: 2013

Journal Articles

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

Yuko Tanaka, MD, Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yoshikazu Ito, MD, PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1894.

https://doi.org/10.1182/blood.V122.21.1894.1894

Published: 2013

Journal Articles

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Seiichiro Katagiri, MD, Tetsuzo Tauchi, MD, Tomohiro Umezu, PhD, Kazuhiro Ohtsuki, PhD, Kenichi Tadokoro, Yoshinori Yamamoto, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 4021.

https://doi.org/10.1182/blood.V122.21.4021.4021

Published: 2013

Journal Articles

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder

Sei-ichiro Yoshizawa, MD, Junko H Ohyashiki, MD, PhD, Michiyo Ohyashiki, MD, Tomohiro Umezu, PhD, Kenshi Suzuki, MD, PhD, Atsushi Inagaki, MD, PhD, Shinsuke Iida, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 2871.

https://doi.org/10.1182/blood.V118.21.2871.2871

Published: 2011

NARROW

Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder

Email alerts

ASH Publications

American Society of Hematology

Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients

Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only